Indian Immunologicals Limited (IIL) is an Indian biopharmaceutical company headquartered in Hyderabad, Telangana. It is engaged in the manufacture of vaccines and biological products for both human and animal healthcare. The company is a wholly owned subsidiary of the National Dairy Development Board (NDDB), the statutory body responsible for India's dairy development programme.
| Name | Indian Immunologicals Limited |
|---|---|
| Type | Biopharmaceutical company |
| Industry | Vaccines and biologicals |
| Headquarters | Hyderabad, Telangana, India |
| Parent organisation | National Dairy Development Board (NDDB) |
| Sectors served | Human healthcare, animal healthcare |
Indian Immunologicals Limited was established by the National Dairy Development Board with the original objective of producing affordable foot-and-mouth disease (FMD) vaccine for India's livestock population, which is critical to the country's dairy economy. Over time, the company expanded its portfolio from veterinary biologicals to include human vaccines, positioning itself as one of the larger vaccine manufacturers in India.
IIL manufactures a range of veterinary vaccines, with foot-and-mouth disease vaccine being its flagship product. Its animal health portfolio also covers vaccines against other diseases affecting cattle, sheep, goats, poultry, and companion animals such as dogs.
The company produces vaccines for human use, including products against rabies, hepatitis, measles, mumps, rubella, tetanus, and diphtheria. IIL supplies vaccines to government immunisation programmes in India as well as to international markets through procurement agencies.
The company operates manufacturing facilities in and around Hyderabad, including units dedicated to bulk antigen production, formulation, and fill-finish operations. It has also developed additional sites in other parts of India to expand capacity for both veterinary and human vaccine production.
As a subsidiary of the NDDB, Indian Immunologicals plays a notable role in India's livestock disease control efforts, particularly through the supply of FMD vaccines used in national control programmes. In the human vaccine segment, the company contributes to the country's domestic vaccine manufacturing capacity, which is significant given India's status as a major global producer of vaccines.